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Abstract
Background: The transcription factor SOX11 plays an important role in embryonic development of the central 
nervous system (CNS) and is expressed in the adult immature neuron but is normally not expressed in any other adult 
tissue. It has recently been reported to be implicated in various malignant neoplasms, including several 
lymphoproliferative diseases, by its specific expression and in some cases correlation to prognosis. SOX11 has been 
shown to prevent gliomagenesis in vivo but the causes and consequences of aberrant expression of SOX11 outside the 
CNS remain unexplained.
Results: We now show the first function of SOX11 in lymphoproliferative diseases, by demonstrating in vitro its direct 
involvement in growth regulation, as assessed by siRNA-mediated silencing and ectopic overexpression in 
hematopoietic malignancies. Gene Chip analysis identified cell cycle regulatory pathways, including Rb-E2F, to be 
associated with SOX11-induced growth reduction. Furthermore, promoter analysis revealed that SOX11 is silenced 
through DNA methylation in B cell lymphomas, suggesting that its regulation is epigenetically controlled.
Conclusions: The data show that SOX11 is not a bystander but an active and central regulator of cellular growth, as 
both siRNA-mediated knock-down and ectopic overexpression of SOX11 resulted in altered proliferation. Thus, these 
data demonstrate a tumor suppressor function for SOX11 in hematopoietic malignancies and revealed a potential 
epigenetic regulation of this developmentally involved gene.
Background
The neural transcription factor SOX11 is a novel diag-
nostic antigen for mantle cell lymphoma (MCL) [1].
However, the prognostic relevance of nuclear expression
of SOX11 in MCL remains unclear since it has been asso-
ciated with both improved and reduced survival [2,3].
Our recent investigations demonstrated that nuclear
staining of SOX11 is also seen in Burkitt Lymphoma (BL)
and precursor B and T cell lymphoblastic neoplasia [4],
indicating a more widespread role in lymphoproliferative
diseases than initially anticipated as also confirmed by
others [5]. Furthermore, analysis of solid tumors revealed
a strong nuclear expression of SOX11 in epithelial ovar-
ian cancer (EOC), which correlated with a prolonged
recurrence-free survival [6], suggesting a functional role
for SOX11 in regulation of tumor growth. Abundant
SOX11 expression has been described in both the fetal
central nervous system (CNS) and CNS-derived malig-
nancies, such as medulloblastoma [7] and malignant
glioma [8]. Furthermore, overexpression of SOX11 has
been shown to prevent tumorigenesis in human glioma
initiating cells [9]. However, our previous study on EOC
demonstrated that SOX11 also might be involved in
growth regulation of malignancies not related to the CNS
[6].
SOX11 belongs to a group of 20 transcription factors
within the high-mobility group (HMG) box protein super
family, which are characterized by high sequence homol-
ogy within their DNA-binding HMG domain [10]. It has
been shown that this HMG domain serves two functions,
i.e. DNA binding as well as partner selection, which may
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Page 2 of 12permit selective recruitment of SOX proteins to specific
promoters and transcription factors [11-13]. To date, the
main function of SOX11 in non-malignant tissues has
been its involvement in neural development [14,15] and
organogenesis [13] during fetal development. Recent data
also suggest an important role for SOX11 as a transcrip-
tional regulator in adult immature neurons [16].
The correlation between SOX11 and differences in sur-
vival in MCL [2,3] and EOC [6] lead us to further investi-
gate the mechanisms underlying its expression. In the
present study, we used functional and epigenetic analyses
of B cell malignancies to demonstrate a regulatory mech-
anism of SOX11 expression on tumor cell growth. In con-
clusion, we provide the first evidence of a growth
regulatory role for SOX11 outside the CNS. Furthermore,
this protein not only has a tumor suppressor function but
is also epigenetically silenced through DNA methylation
in a subset of B cell malignancies.
Results
Analysis of DNA methylation of the SOX11 promoter region
Epigenetic regulation of SOX11 expression was investi-
gated by studying promoter methylation. Analysis of the
2000 bp region upstream of the transcription start site of
SOX11 identified four CpG islands (Figure 1). DNA
hypermethylation of such islands is a common event in
tumor progression and leads to silencing of the corre-
sponding gene [17]. The methylation status of the SOX11
promoter was assessed in nineteen cell lines, originating
from different B cell malignancies, including eight MCL,
three DLBCL, four FL, three BL and one acute monocytic
leukemia (MONO-L) (Table 1). Initially, seven cell lines
were assessed for presence of methylated CpGs in all four
identified CpG islands (Figure 1). However only the CpG
island closest to transcription start was determinative for
SOX11 expression in all seven cell lines (data not shown),
thus in the remaining analyses bisulfite sequencing was
performed on the CpG island adjacent to the SOX11 tran-
scription start site, covering 28 unique CpG sites (Figure
1).
A striking difference in SOX11 promoter methylation
was detected between MCL and non-MCL lymphoma
cell lines (Figure 2). The results were confirmed on indi-
vidual alleles with TOPO-TA cloning for seven of the cell
lines (Table 1). Analysis of non-MCL cell lines revealed
high levels of SOX11 promoter methylation in all cases
(11/11), corresponding to a lack of both SOX11 mRNA
and protein expression (Figure 2). In contrast, SOX11
promoter methylation was absent in the majority (7/8) of
MCL-derived cell lines, with SOX11 mRNA and protein
expression being evident in 6 of the cell lines (GRANTA-
519, HBL-2, JEKO-1, REC-1, SP53 and Z138) (Figure 2).
UPN-2 was partially methylated, and lacks SOX11
expression. JVM-2 was the only MCL cell line lacking
SOX11 mRNA and protein, although the promoter was
not methylated in any of the 28 CpG's investigated.
Untreated clinical specimens were collected to assess
the methylation status in primary material from MCL (n
= 4), FL (n = 5) and a single case of DLBCL (see Addi-
tional File 1: Table S1). To enable specific methylation
analysis, the B cells were purified, using positive selection
on CD19-coated beads, and purity was assessed, using
flow cytometry analysis (see Additional File 1: Table S1).
Thus, the analyzed samples contained predominantly B
cells, however, the frequency of tumor B cells will vary
between entities.
In agreement with the in vitro data a difference in DNA
methylation status of the SOX11 promoter was evident
between expressing and non-expressing primary B cell
lymphomas. The SOX11 promoter was not methylated in
primary MCL (Figure 3A), which was consistent with
protein analysis (Figure 3A lower panel). However, exten-
sive (>70%) DNA methylation was seen in the DLBCL
and FL samples, apart from FL5 where less (50%) of the
alleles were methylated (Figure 3B, upper panel), possibly
due to a sub-population of non-malignant cells. As
expected, none of the primary FL or DLBCL samples
expressed the SOX11 protein (Figure 3B, lower panel).
This is in agreement with both previous gene expression
data [1] and current RT-PCR data on DLBCL cell lines
(Figure 2) and thus confirms that the cytoplasmic stain-
ing seen in IHC for DLBCL and other non-MCLs [1,3-
5,18] should not be considered to be specific for SOX11.
Consequently, the lack of SOX11 promoter methylation
in MCL compared to the methylated FL and DLBCL sam-
ples, points towards methylation-mediated SOX11 silenc-
ing in B cell malignancies.
SOX11 knockdown in MCL cell lines results in increased 
cellular proliferation
The functional effect of SOX11 was then investigated in
well-characterized in vitro models of MCL (GRANTA-
519 and REC-1). siRNA mediated gene silencing (see
Additional File 1: Table S3) resulted in a significant
decrease of both SOX11 mRNA (Figure 4A) and protein
(Figure 4B) and lead to an almost 100% increase in prolif-
eration at 48 hrs (Figure 4C). The follicular lymphoma
cell line did not express any SOX11 and no change in pro-
liferation was consequently detected (data not shown).
The effect on mRNA expression reached a maximum
decrease at 24 hrs for GRANTA-519 and at 48 h for REC-
1 (Figure 4A), while the subsequent decrease in protein
level was most pronounced at 72 h for GRANTA-519 and
at 48 h for REC-1 (Figure 4B). The functional effect on
cell proliferation seen at 48 h for both MCL cell lines (Fig-
ure 4C), demonstrates a growth regulatory role for
SOX11.
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To further investigate the direct effect of SOX11 regula-
tion, transient over-expression of SOX11 in a panel of cell
lines was performed (see Table 1). SOX11 cDNA (see
Additional File 1: Table S2) and a control vector contain-
ing GFP were introduced via nucleofection. Cell viability
was 80-95% in all cell lines 24-48 h after nucleofection of
both control and SOX11 plasmid (data not shown). Dif-
ferent levels of mRNA overexpression were evident at 24
h (Figure 5A) in both SOX11 negative (SC-1, JVM-2) and
positive (BJAB, JEKO-1, GRANTA-519 and Z138) cell
lines, resulting in different expression of SOX11 protein
(Figure 5B). However, no direct correlation between
mRNA and protein levels could be seen, in fact BJAB and
SC-1 showed strongest increase in protein level (Figure
5B), although the amount of SOX11 mRNA was similar in
all cell lines but Z138. The proliferation at 24 and 48 h
clearly indicated that all cell lines grew significantly
slower due to the SOX11 overexpression, with the most
pronounced effect at 48 h for all cell lines but BJAB, in
which decreased proliferation was seen already at 24 h
(Figure 5C). The strongest reduction in proliferation was
seen for GRANTA-519, Z138 and JVM-2, the latter being
SOX11-negative in wt cells (Figure 5C). Thus, SOX11
directly regulates growth in all cell lines analyzed, inde-
pendent of their original SOX11 status.
Global gene expression analysis identified the Rb-E2F 
growth regulatory pathway to be involved in SOX11-
related growth reduction
Both siRNA-mediated knock-down and forced overex-
pression of SOX11 result in change in proliferation of tar-
get cells (Figure 4c and 5c). To understand the basic
mechanisms involved in this macroscopic event, global
gene expression analysis of SOX11-overexpressing and
control cells was performed using the MCL cell lines
GRANTA-519 and JEKO-1.
4861 transcripts (see Additional File 2) were found to
be differentially expressed in GRANTA-519 and JEKO-1
at either 24 or 48 h of ectopic SOX11-overexpression.
Table 1: Cell lines included in the study and type of method for DNA methylation analysis.
Cell line* Lymphoma** Supplier DNA methylation analysis
GRANTA-519 MCL DSMZ D,T
SP53 MCL ***** D,T
Z138 MCL **** D,T
HBL-2 MCL D
JEKO-1 MCL DSMZ D
JVM-2 MCL DSMZ D
REC-1 MCL DSMZ D
UPN-2 MCL D,T
WSU-NHL FL DSMZ D,T
SC-1 FL DSMZ D
RL FL DSMZ D
DOHH-2 FL DSMZ D
SU-DHL-8 DLBCL *** D,T
ULA DLBCL *** D
KARPAS DLBCL *** D
RAMOS BL DSMZ D
RAJI BL DSMZ D
DAUDI BL DSMZ D
THP-1 MONO-L DSMZ D
*The SOX11 gene was sequenced in all cell lines
** see text for abbreviations
*** Kindly provided by Dr Kristina Drott, Lund University
**** Kindly provided by Dr Martin Dyer at Leicester University
***** Kindly provided by Dr Mats Ehinger, Lund University
D direct sequencing
T TOPO-TA cloning of individual alleles
DSMZ, Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH
Gustavsson et al. Molecular Cancer 2010, 9:187
http://www.molecular-cancer.com/content/9/1/187
Page 4 of 12
Figure 1 CpG islands in the SOX11 promoter region. Analysis of 2000 bp upstream of SOX11 transcription start revealed four CpG islands with a GC 
content above 50 percent http://www.urogene.org/methprimer/index1.html [45]. CpG dinucleotides are represented as vertical bars. Primers that 
amplified -435 to -222 were used in bisulfite sequencing to compare the methylation status of the SOX11 promoter region with SOX11 expression.
Figure 2 Methylation status of SOX11 promoter region correlated to SOX11 expression. Methylation status of SOX11 promoter (described as 
percentage of methylated CpGs of 28 possible CpG methylation sites) was analyzed by direct bisulfite sequencing (right Y-axis) and correlated to 
SOX11 expression on mRNA (left Y-axis) and protein level in nineteen lymphoid or monocytic cell lines (Table 1). Generally, all samples with a ΔCT 
(SOX11+RT, SOX11-RT) < |2| was considered negative and the RQ was set to 0.01 for those samples. RQ values are related to the SOX11 expression in 
GRANTA-519 and the error bars show the 95% confidence interval
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for 24 and 48 h of SOX11-overexpression were imported
into Ingenuity Pathway Analysis (IPA, Ingenuity Systems,
Mountain view, CA). IPA analysis (Ingenuity Systems)
recognized 3647 individual genes among the 4861
GeneChip transcripts and identified "cell cycle" as the
main molecular function associated with SOX11-induced
genes. The identified cell cycle-associated transcripts (n
= 355) are marked with an asterisk in Additional File 2.
The strong correlation between the differentially regu-
lated genes and cell cycle function is consistent with the
observed change in proliferation (Figure 5c) emphasizing
the biological relevance of the differentially regulated
genes in relation to MCL and SOX11. Furthermore, IPA
analysis was used to identify the main canonical pathway
associated with the differentially regulated genes. The
identified pathway, "Molecular Mechnisms in Cancer", is
shown in full in Supplementary Figure S1 for 24 h (S1a)
and 48 h (S1b) of ectopic SOX11-overexpression. Sec-
tions of the canonical pathway are shown in Figure 6a-d.
Among others, this includes the Rb-E2F signaling path-
way, known to be of major importance in MCL [19].
Figure 3 SOX11 DNA methylation and protein expression in primary lymphoma samples. Methylation patterns of SOX11 promoter in clinical 
specimens was determined by bisulfite sequencing of individual alleles and correlated to SOX11 protein expression. Every row represents a unique 
allele and the columns represent a potentially methylated CpG site. a) In MCL samples, the promoter stays unmethylated and SOX11 is detectable. b) 
The lack of SOX11 protein in FL and DLBCL is accompanied by 50-100% methylated alleles.
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including p16INK4A and p14ARF, and TGF-β at 24 h may
promote the change in gene expression seen comparing
samples after 24 and 48 h of SOX11-overexpression. At
48 h, up-regulation of anti-proliferative genes, including
BRCA1 and Smad2/3, and the down-regulation of E2F1
(Figure 6b) is consistent with the decrease in proliferation
seen for GRANTA-519 and JEKO-1 at this time point
(Figure 5c). The differentially regulated genes are marked
in red or green corresponding to a mean fold change of
≥1.2 or ≤1.2, respectively as shown for 24 h (Figure 6a)
and 48 h (Figure 6b) of SOX11-overexpression. The
remaining differentially regulated genes are marked in
grey. The latter represent genes that have different kinet-
ics or regulation in GRANTA-519 and JEKO-1, being up
or down-regulated at either 24 or 48 h of SOX11-overex-
pression.
In all, Gene Chip analyses demonstrate that the major
growth-promoting signaling pathway in MCL, the Rb-
E2F cell cycle regulatory pathway, is affected upon
SOX11-induced overexpression and mediates the
observed growth reduction.
Discussion
Recent data have suggested a functional role for the
developmentally associated transcription factor SOX11
outside the CNS [2,3,6], and this marker has been shown
to be expressed in specific subtypes of B cell lymphomas
[1,4,18], as well as in solid tumors [6]. Furthermore, the
potential regulatory role of SOX11, indicated by its asso-
ciation with clinical features, such as survival [2,3,6],
require further investigations to understand the underly-
ing biology and potential clinical application of this
marker.
Gene expression can be regulated by epigenetic mecha-
nisms, such as DNA methylation of CpG islands in the 5'
promoter region [20,21]. Methylation-mediated silenc-
ing of various genes, often tumor suppressor genes, is a
well studied phenomenon in many cancers [22], since
such methylation provides a growth advantage for the
malignant cells. An increasing number of hypermethy-
lated genes have been reported in lymphomas [23-30],
where they have been shown to be involved in various
cellular functions, such as cell cycle control [23], cytokine
signaling [27], DNA repair and apoptosis [28].
Figure 4 siRNA knock-down of SOX11 increase proliferation. Effect of the siRNA induced knock-down of the SOX11 gene in GRANTA-519 and REC-
1 on, a) mRNA level at 24 and 48 h; b) protein level at 48 h and 72 h, respectively, and c) proliferation at 24, 48 and 72 h. A control siRNA targeting the 
Eg5 gene was used as a positive control (only shown in b). All values in a) are relative quantity values (RQ) compared to the scrambled siRNA control. 
The data is representative of three independent assays. In a) the error bars show the 95% confidence interval, while in c) ±1 SD is shown.
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of CpG islands, and bisulfite sequencing demonstrated a
strong correlation between promoter methylation status
and SOX11 mRNA and protein levels in both B cell lym-
phoma cell lines and primary tumors. Thus, as previously
reported, data from cell lines can represent the methyla-
tion status of primary malignant tissue well [31]. How-
ever, as our experiments illustrate, and also reported by
others, the magnitude of methylation is more pro-
nounced in cell lines, since they often display either a full
methylation or no methylation at all [32]. Altogether, it is
clear that the absence of SOX11 expression is tightly cou-
pled to a methylated promoter in primary tumor samples,
however no specific determinative CpG position could be
identified as most alleles were either fully methylated or
unmethylated.
In addition to investigating the cause of differential
SOX11 expression, we also explored the relationship
between SOX11 and cellular growth, as a correlation with
improved survival has been reported [1,3]. SOX11 func-
tion in the CNS has previously been assessed, using
siRNA in a mouse neuroblastoma cell line and in cultured
mouse dorsal root ganglia neurons, where SOX11 was
shown to modulate the levels of several other unrelated
mRNAs involved in cell survival and death, suggesting an
anti-apoptotic role [33]. In contrast, SOX11 was recently
shown to prevent gliomagenesis in vivo by induced neu-
ronal differentiation and abolished expression of onco-
genic plagl1 [9]. Recent clinical studies have shown both a
positive and negative correlation of SOX11 to survival
and further studies are consequently needed to fully
explore the clinical implications of this marker [2,3,6]. In
the present study, transient knock-down experiments
confirm a growth regulatory role for SOX11 in B cell
malignancies, as decreased levels result in increased pro-
liferation in several in vitro models of MCL. To further
clarify if SOX11 is the limiting factor in a signaling cas-
cade or if SOX11 possibly exhibits a master regulatory
property, we overexpressed SOX11 in different B cell lym-
phoma cells lines with variable degree of wild-type
SOX11 expression. Overexpression was achieved in all
cell lines, independent of the original SOX11 status, and
resulted in an increase in SOX11 protein. Of note, all cell
lines were functionally affected and their growth rates
Figure 5 Overexpression of SOX11 decrease proliferation. a) mRNA expression of SOX11 at 24 h after overexpression of the SOX11 gene in six B 
cell lymphoma cell lines. b) Western blot analysis at 24 h confirms SOX11 overexpression in SOX11 transfected samples (right), compared to wt (left) 
and control vector (middle), loading control (GAPDH) is seen below c) Proliferation assay at 48 h after transfection showed decreased cell growth in 
all cell lines but BJAB where the decrease could be seen already after 24 h. In a) all values are relative quantity (RQ) compared to the GFP value for 
GRANTA 519. In c) all cell lines are compared to their respective GFP value. The data is representative of three independent assays. In a) the error bars 
show the 95% confidence interval, while in c) ±1SD is shown.
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tion upon increasing SOX11 levels confirms that SOX11
is a master growth regulator.
It is known since previously that proliferation in MCL
is partly driven by an overexpression of CCND1, which
leads to an increased ability to pass through the G1/S cell
cycle checkpoint [34]. Using global gene expression anal-
ysis we now show that the CCND1-related Rb-E2F path-
way [19,35] is affected by the increased level of SOX11.
Among others, up-regulation of the CDKN2A locus, cod-
ing for p16INK4A and p14ARF, is seen already at 24 h of
ectopic SOX11-overexpression. The CDKN2A locus
encode both p16INK4A and p14ARF, but the proteins have
no sequence homology due to alternative reading frames
[36]. The precise mechanisms of CDKN2A regulation
and induction is unknown, but it has been shown that
p16INK4A and p14ARF levels responds to, (i) external stress
signals, (ii) Jun, Ets and Id families of transcription factors
and (iii) hyperproliferative signals from for example Ras,
Myc or deregulated E2F, as reviewed by Lowe and Sherr
[37]. Thus, it remains to be determined how SOX11
induces changes to the Rb-E2F signaling pathway
although it is of major biological interest that this MCL-
associated protein affects the same signaling pathway as
CCND1.
In agreement with the observed decrease in prolifera-
tion both p16INK4A and p14ARF possess anti-proliferative
functions [36,38] and constitute two of the three path-
ways that control the G1/S transition of the cell cycle and
are thus targeted in many tumors [39]. E2F1 is down-reg-
ulated at 48 h and is one of the down-stream targets of
p14ARF. It has been suggested that E2F1 is the limiting
factor for cell cycle transition [36], and the decrease may
thus directly contribute to the observed growth reduc-
tion.
Figure 6 Gene Chip analysis reveal SOX11-induced regulation of Rb-E2F and TGF-β signaling pathways. Ingenuity Pathway Analysis identified 
the canonical pathway "Molecular Mechanisms in Cancer" as highly associated with the 3647 deregulated genes. Within this pathway RB-E2F (A and 
B) and TGF-β (C and D) signaling is regulated in a time-dependent manner as shown after 24 h (A and C) and 48 h (B and D) of ectopic SOX11-over-
expression. The differentially regulated genes are marked in red or green when the mean fold change for GRANTA-519 and JEKO-1 was ≥1.2 or ≤1.2. 
The remaining differentially regulated genes, including genes with different kinetics in the two cell lines, are marked in grey.
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induces expression of down-stream genes, including
TGFβR1, SMAD2/3 and TAB1/2 at 48 h. Of note, we have
previously demonstrated that MCL cell lines are respon-
sive to TGF-β-mediated decrease in proliferation when
the corresponding receptor is available [40]. Thus, the
up-regulation of TGF-βR seen at 48 h emphasizes the
need for a functional receptor to achieve TGF-β-medi-
ated growth reduction. Consequently, it is likely that the
anti-proliferative activity of TGF-β together with reduced
levels of E2F1 is directly involved in growth reduction
induced by ectopic SOX11-overexpression. The anti-pro-
liferative effect of TGF-β is widely known and its dual
role as both tumor suppressor and pro-metastatic media-
tor makes it an interesting target for intervention [41-43].
Conclusions
We have for the first time shown that the expression of
the transcription factor SOX11 is inversely correlated to
specific promoter methylation in hematopoietic malig-
nancies and that SOX11 has growth regulatory proper-
ties. Gene Chip analysis revealed that TGF-β and
components of the Rb-E2F proliferative pathway, includ-
ing E2F1 and the CDKN2A locus, are involved in the
SOX11-induced growth reduction. Thus, based on both
experimental and previous clinical observations we sug-
gest that SOX11 can act as a master regulator of lym-
phoid tumor cell growth.
Methods
Cultivation of cell lines
Nineteen lymphoma cell lines were used to study SOX11
including eight MCL, four follicular lymphoma (FL),
three diffuse large B cell lymphoma (DLBCL), three
Burkitt lymphoma (BL) and one acute monocytic leuke-
mia (MONO-L), as shown in Table 1. Most cell lines were
provided and authenticated by DSMZ (Table 1). All cell
lines were cultured in RPMI-1640 medium (HyClone,
Sout Logan, UT) supplemented with 10% (v/v) fetal
bovine serum (Invitrogen Gibco, Carlsbad, CA, USA) and
2 mM L-Glutamine (Sigma-Aldrich, St. Louis, MO, USA),
hereafter referred to as R10 medium, except ULA which
was cultured in 45% optiMEM (HyClone), 45% IMDM
(HyClone) supplemented with 10% (v/v) fetal bovine
serum (Invitrogen).
Collection and purification of primary samples
Lymphocytes were isolated from four MCLs, five FLs and
one DLBCL through density centrifugation, as previously
described [44]. All five FL samples and two of the MCL
samples (MCL1 and MCL6) were purified by positive
selection, using a CD19 specific antibody (clone HD37,
DAKO, Glostrup, Denmark) coupled to Dynabeads Pan
Mouse IgG magnetic beads (Invitrogen Dynal), according
to the protocol of the manufacturer. Flow cytometry was
used to determine the purity of MCL 3 and 4 and the
DLBCL. Patient material information is shown in Addi-
tional File 1: Table S1.
DNA methylation analysis
MethPrimer http://www.urogene.org/methprimer/
index1.html[45] was used to analyze the 2000 bp region
directly upstream of the SOX11 transcription start site
(the SOX11 promoter region) for the presence of CpG
islands. Using the MethPrimer default algorithm, three
CpG islands were identified as >200 bp regions with G
and C contents >50% and Observed/Expected CpG-rates
of >0.6. One additional CpG island was detected when
the region size constraint was lowered to 100 bp without
altering the other criteria (Figure 1). The methylation sta-
tus of the 5'-promoter region was determined by sodium
bisulfite sequencing [46] of the 213 bp CpG island located
-435 to -222 bp upstream of the SOX11 transcription
start site. Briefly, total genomic DNA was extracted from
five million cells per cell line or primary samples, using
QIAamp DNA MINI kit (QIAgen) according to the pro-
tocol of the manufacturer. To convert unmethylated cyto-
sine to uracil, we performed bisulfite conversion of 0.5 - 1
μg of DNA with EpiTect Bisulfite Kit (QIAgen). The CpG
island was amplified from bisulfite converted DNA, using
primers 5'-AGA GAG ATT TTA ATT TTT TGT AGA
AGG A-3'and 5'-CCC CCT TCC AAA CTA CAC AC-3'
and Platinum Taq DNA polymerase (Invitrogen). PCR
products were both directly sequenced as well as ligated
into the vector pCR.21-TOPO (Invitrogen) for clonal
analysis. Sequencing was performed by Eurofins MWG
Operon (Ebersberg, Germany and GATC Biotech (Kon-
stanz, Germany). Quality control of methylation data was
performed in a standardized manner, using the BiQ Ana-
lyzer software [47], http://biq-analyzer.bioinf.mpi-inf.
mpg.de/index.php. Images of CpG methylation for fig-
ures 3A-C were constructed using the BDPC web server
[48], using output files from BiQ Analyzer. All amplicons
included in the study had, (i) bisulfite conversion rates
above 95% for unmethylated non-CpG C:s to T:s, and (ii)
sequence similarity above 90% compared to the original
genomic sequence.
Nucleofection of cell lines with SOX11-specific siRNA or 
overexpression plasmid
The Amaxa protocol http://www.lonzabio.com/proto-
cols.html for nucleofection of suspension cell lines was
followed, using program 0-017 and Cell Line Nucleofec-
tor Solution T (Amaxa Biosystems, Cologne, Germany).
For the knock-down experiments, 5 × 106 cells were
mixed with 50 pmol of siRNA (Ambion, Austin, TX,
USA) in each reaction and a scrambled sequence and
GFP-producing plasmid were used as controls. The
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gene can be found in Additional File: Table S3. For the
overexpression experiments, 5 × 106 cells were mixed
with 2 μg of OmicsLink™Expression Clone for SOX11
(EX-M0425-M60, the sequence can be found in the Addi-
tional File 1: Table S2) in each reaction and a GFP control
vector was used as a control (both from GeneCopoeia,
Germantown, MD, USA).
RNA isolation and Real Time-qPCR analysis of wt and 
SOX11-knocked/overexpressed cell lines
The relative quantity (RQ) of SOX11 mRNA in various wt
cell lines was identified using Real Time-quantitative PCR
(RT-qPCR). The cells were lysed and cDNA synthesis
performed using the Fast SYBR Green Cells-to-CT kit
(Applied Biosystems), according to the protocol of the
manufacturer. Briefly, 104 cells were washed in PBS, lysed
and treated with DNase. Lysates were reversely-tran-
scribed and cDNA amplified in three technical replicates
with the following primer specific either for SOX11 or the
house-keeping gene GAPDH (250 nM, MWG, High-
Point, NC, USA); GAPDH: 5'-TGGTATCGTG-
GAAGGACTC-3' and 5'-AGTAGAGGCAGGGATGAT
G-3', SOX11-t: 5'-GGTGGATAAGGATTTGGAT TCG-
3' and 5'-GCTCCGGCGTGCAGTAGT-3'. q-PCR condi-
tions were as follows: enzyme activation 20 seconds at
95°C, PCR cycle denaturation for 3 seconds at 95°C and
anneal/elongation 30 seconds at 60°C run on a Fast 7500
real-time qPCR system (Applied Biosystems). All samples
were run in triplicates. In the reverse-transcription, a
control sample was run containing lysate but no reverse
transcriptase (RT), to check for background amplification
of genomic SOX11 and GAPDH. A ΔCT > 4 for GAPDH
(+RT) and GAPDH (-RT) was achieved for all cell lines.
Similarly, the ΔCT for SOX11 (+RT) and SOX11 (-RT) was
used as a qualitative control to determine if SOX11 was
expressed or not. Generally, all samples with a ΔCT
(SOX11+RT, SOX11-RT) < |2| was considered negative and the
RQ was set to 0.01 for those samples. Finally, RQ is calcu-
lated as 2-(ΔΔCT(SOX11-GAPDH)) comparing each cell line to
GRANTA-519. All the error bars related to qPCR data
have been calculated using the standard error (SE) with a
95% confidence level.
For the over-expression experiments the Fast SYBR
Green Cells-to-CT kit (Applied Biosystems) was used for
lysis of 0.5-1.0*105 cells and subsequent cDNA synthesis
as described above. The SOX11-t and GAPDH primer
sets were used for amplification
In the knock-down experiments RNA isolation was car-
ried out, using Trizol (Invitrogen) as previously described
[44]. The cDNA synthesis was performed, as outlined in
the RevertAid™First Strand cDNA Synthesis kit-protocol
(Fermentas). 1 μg of RNA was mixed with 0.2 μg random
hexamer primers, and a reverse transcriptase was added
to produce cDNA. Samples for RT-qPCR were prepared
following the iQ™SYBR Green Supermix protocol (Bio-
Rad, Hercules, CA, USA). The concentration of cDNA
was 1.25-2.5 μg/l. The primers were as above but primers
for Eg5 were included and a different set of SOX11 prim-
ers were used as follows: SOX11-u: 5'-CCAGGACA-
GAACCACCTGAT-3' and 5'-CCCCACAAACCACTCA
GACT-3', Eg5: 5'-GTTTGGCCATACGCAAAGAT-3'
and 5' - GAGGATTGGCTGACAAGAGC-3'. The RT-
qPCR was run in triplicate, using a 2-Step Amplification
and melt-curve program (Bio-Rad) with GAPDH as the
endogenous control.
Protein purification and quantification
0.5-2 × 106 cells were harvested, washed and placed in
200 μl lysis-buffer (1% NP40/Protease Inhibitor cocktail
(Roche, Basel, Switzerland) in PBS) and incubated on ice
for 30 min. Centrifugation (16,000 × g at 4°C for 30 min)
was used to remove cell debris. Protein concentrations
were determined using the BCA Kit for Protein Determi-
nation (Sigma-Aldrich) with BSA as a standard (0.08 - 0.4
mg/ml). The samples were mixed with BCA working
reagent, incubated at 37°C for 30 min, and absorbance
measured at 562 nm.
Western Blot analysis of SOX11-knockdown and differential 
expression
Protein lysates, 3 or 7 μg for knock-down experiments,
3.5 μg for overexpression experiments and 32 μg for wild-
type expression in nineteen lymphoma cell lines and fif-
teen primary specimens were run on NuPAGE 10% Bis-
Tris gels (Invitrogen) under reducing conditions for ~45
min at 130 V. Separated proteins were blotted onto PVDF
membranes, Amersham Hybond-P (GE Healthcare, Upp-
sala, Sweden) for 30 min (15 V) and blocked over night in
5% milk PBS. SOX11 protein expression was verified
using anti-Sox-11C-term (Figure 2, 3, 4 or Sox-11N-term (Fig-
ure 5) antibodies, as previously described [1,4]. Primary
antibodies Eg5 (Becton Dickinson, Franklin Lakes, NJ,
USA) or GAPDH (Abcam) were used as loading control.
HRP-labeled swine anti-rabbit antibody or rabbit anti-
mouse antibody (DAKO) was used as secondary antibody
and detection was made with SuperSignal West Femto
Max Sensitivity Substrate (Pierce Biotechnology Inc.,
Rockford, IL), according to the protocol of the manufac-
turer. Blots were developed, using the SuperSignal West
Femto Maximum Sensitivity Substrate (Nordic Biolabs,
T228;by, Sweden) and detected with either with ECL
Hyperfilm (GE Healthcare) in Kodak X-OMAT 1000 pro-
cessor (Kodak Nordic AB, Upplands V228;sby, Sweden)
or using a chemiluminescence scanner and CCD camera
(Bio-Rad Laboratories, Hercules, California).
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All proliferation assays were quantified using Methyl-3H-
Thymidine (MTT) incorporation, as previously described
[49]. 50 000 cells were plated in triplicates for each sam-
ple. For all proliferation results, the ± 1 standard devia-
tion (SD) is shown.
Isolation of tRNA for GeneChip Whole Transcript analysis
GRANTA-519 and JEKO-1 cells were nucleofected with
SOX11-GFP or control GFP-containing vector, as
described above, and 100 000 cells were washed once in
PBS and lysed in 300 μl Trizol (Life Technologies, Gaith-
ersburg, MD). The RNA was precipitated using chloro-
form/isopropanol extraction and dissolved in 6 μl of
RNA-free H2O. The integrity and quantity of the RNA
was assessed using Agilent 2100 bioanalyzer with the
RNA 6000 Nano LabChip® reagent set (Agilent Technolo-
gies Inc., Santa Clara, CA, USA) and stored at -20°C. For
all arrays 300 ng tRNA starting material was used for the
first strand cDNA synthesis which was followed by ampli-
fication, fragmentation, labeling, hybridization, washing
and scanning, all performed according to the Affymetrix
standard protocol "GeneChip® Whole Transcript (WT)
Sense Target Labeling Assay User manual, P/N 701880
Rev.5 (Affymetrix Inc., Santa Clara, CA). The labeled
cRNA was hybridized to the Human Gene ST 1.0 arrays
(Affymetrix Inc.). All arrays passed the initial quality con-
trol using assessment of hybridization, amplification con-
trols and noise levels as defined by Affymetrix Inc.
Bioinformatic analysis of Gene Chip data
Raw data was extracted from Human Affymetrix Gene
arrays, HuGene ST 1.0, using the Command Console
software package (Affymetrix). Quantile normalization
using RMA and quality control was done in the Expres-
sion Console 1.0 software (Affymetrix). Normalized data
was imported into Gene Spring GX 11.0 (Agilent Tech-
nologies Inc.) for fold change analysis. Fold change analy-
ses for 24 and 48 h treatments were performed for
GRANTA 519 and JEKO-1, comparing SOX11 overex-
pression to control vector. For each of the cell lines, genes
that had a 1.2 fold change comparing SOX11 to control
vector, at either 24 h or 48 h were selected. Genes that
were differentially expressed in both cell lines were
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